Capture FDA Regulatory Sovereignty via SBIR Phase II Dependency
- Organization
- NSF SBIR Phase I program funding medical device R&D without providing regulatory clearance infrastructure
- Sector
- DELEON TECHNOLOGIES principals desperate for FDA pathway to secure Phase II funding
- Location
- Newark, DE / Atlanta, GA
Source Reference
Executive Context
NSF awarded DELEON TECHNOLOGIES $305K SBIR Phase I funding to develop a disposable microfluidic chip for urine analysis, creating a classic "SBIR Valley of Death" scenario where government-funded technical capability exists without commercial infrastructure for FDA clearance, manufacturing scale, or data monetization.
Catalyst / Timing
DELEON TECHNOLOGIES has $305K NSF SBIR Phase I funding for medical device R&D but zero FDA regulatory pathway expertise or infrastructure - they must navigate 510(k) clearance for Phase II success but lack the specialized knowledge and institutional relationships required
Projected Yield
15% equity stake in DELEON TECHNOLOGIES (valued at $2-5M post-Phase II) + 20% revenue share on all chip sales
Structural Friction
• Vulnerability: DELEON TECHNOLOGIES has $305K NSF SBIR Phase I funding for medical device R&D but zero FDA regulatory pathway expertise or infrastructure - they must navigate 510(k) clearance for Phase II success but lack the specialized knowledge and institutional relationships required • Capital yield: 15% equity stake in DELEON TECHNOLOGIES (valued at $2-5M post-Phase II) + 20% revenue share on all chip sales • Resource capture: Exclusive ownership of the 'regulatory wrapper' IP package for urine microfluidic chips • Influence capture: De facto regulatory czar position for all future DELEON medical device submissions • Sovereignty yield: Control over FDA submission timeline and strategy, creating critical path dependency for DELEON's entire commercialization • Required vectors: Vector: Corporate Law & Entity Structure Analysis, Vector: FDA Medical Device Regulatory Expertise, Vector: SBIR/STTR Grant Compliance, Vector: Business Development & Partnership Negotiation
Required Capabilities
Vector: Corporate Law & Entity Structure Analysis
Primary executor: Phase 1: Entity Intelligence & Principal Mapping: Search Delaware Division of Corporations database for DELEON TECHNOLOG
Vector: FDA Medical Device Regulatory Expertise
Supporting vector for: Capture FDA Regulatory Sovereignty via SBIR Phase II Dependency
Vector: SBIR/STTR Grant Compliance
Supporting vector for: Capture FDA Regulatory Sovereignty via SBIR Phase II Dependency
Vector: Business Development & Partnership Negotiation
Supporting vector for: Capture FDA Regulatory Sovereignty via SBIR Phase II Dependency
Execution Protocol
Execution Protocol Locked
A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.